Ion Channel Screening

Whether you want to explore an ion channel as a potential new target or understand cardiovascular liability, seizure or other liabilities, ApconiX can help you with our electrophysiology expertise, customer-focused flexibility and rapid delivery of high data quality. The services we offer include hERG screening and CiPA assays, a seizure panel of 15 ion channels and a MicroElectrode Array assay using human derived neuronal stem cells. These are complemented by a wide range of assay development and ion channel screening services.

The Ion Channel Screening Services’ pages have been translated into Spanish and Catalan.  Please click on the flags below to select a language: 

MicrosoftTeams image 28 | ApconiX
Spain Flag
French 1 | ApconiX

Make safety part of drug design with early drug discovery screening.

cardiac | ApconiX

Rapid high quality ion channel screening
for hERG and the CiPA paradigm

Cardiac Liability
sezure | ApconiX

An integrated in vitro screening approach for seizure liability to support hazard identification and decision making in early drug discovery

Seizure Liability
additional | ApconiX

Including assay development, manual patch clamp, sustainability and investigative research.

Additional Capabilities
videosnippet button | ApconiX

Directors and co-founders Dr Michael Morton
and Dr Richard Knight are joined by
members of the laboratory team
Dr Kimberly Rockley and Hannah Jennings.

Ion Channel Screening (Video)
cardiac for rollover2 | ApconiX

Director and co-founder Dr Michael Morton and Dr Kimberly Rockley discuss the benefits of early ion channel screening in this DDW podcast

DDW Podcast